CVS also announced that AbbVie and CVS-owned company Cordavis, which launched in August, will produce a co-branded version of Humira that will be made available to customers in the second quarter of ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

The first of at least 8 adalimumab biosimilars has finally launched in the United States after being kept off the market for years due to settlement agreements with the maker of the reference product, ...

Please provide your email address to receive an email when new articles are posted on . Simlandi (adalimumab-ryvk) hit the market as first interchangeable, citrate-free Humira biosimilar in a ...

Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...

Alvotech (NASDAQ:ALVO) and partner Teva Pharmaceuticals (NYSE:TEVA) announced Friday the U.S. Food and Drug Administration (FDA) approval for their arthritis injection, Simlandi (adalimumab-ryvk).

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Celltrion USA’s Yuflyma as the ninth biosimilar to adalimumab for all eligible indications ...

A long-awaited moment for consumers arrived last year when patent protection expired on the nation’s most prescribed medicine, AbbVie’s wildly successful — and costly — rheumatoid arthritis drug ...

JERUSALEM, May 8 (Reuters) - Teva Pharmaceutical Industries (TEVA.TA), opens new tab said it was set to launch its long awaited biosimilar of AbbVie's (ABBV.N), opens new tab blockbuster arthritis ...

People taking adalimumab (Humira) for moderate-to-severe hidradenitis suppurativa (HS) saw better results across the board when the drug was combined with a surgical intervention. That's according to ...

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership ...